These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35933523)

  • 21. BCR-ABL1 positive AML or CML in blast crisis? A pediatric case report with inv(3) and t(9;22) in the initial clone.
    Behrens YL; Schienke A; Davenport C; Lentes J; Tauscher M; Steinemann D; Rasche M; Knirsch S; Joachim S; Reinhardt D; Schlegelberger B; Göhring G
    Cancer Genet; 2021 Jun; 254-255():70-74. PubMed ID: 33647814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
    Boer JM; Steeghs EM; Marchante JR; Boeree A; Beaudoin JJ; Beverloo HB; Kuiper RP; Escherich G; van der Velden VH; van der Schoot CE; de Groot-Kruseman HA; Pieters R; den Boer ML
    Oncotarget; 2017 Jan; 8(3):4618-4628. PubMed ID: 27894077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
    Duan MH; Li H; Cai H
    Leuk Res; 2017 Aug; 59():8-11. PubMed ID: 28527402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors.
    Song HY; Noh H; Choi SY; Lee SE; Kim SH; Kee KM; Yoo HL; Lee MY; Kang KH; Suh JH; Yang SY; Jang EJ; Lee JI; Kim DW
    Cancer Med; 2018 Oct; 7(10):5107-5117. PubMed ID: 30171671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
    Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
    Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
    Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
    Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal Residual Disease Eradication in CML: Does It Really Matter?
    Tantravahi SK; Guthula RS; O'Hare T; Deininger MW
    Curr Hematol Malig Rep; 2017 Oct; 12(5):495-505. PubMed ID: 28852963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three atypical BCR/ABL transcripts detected simultaneously in a Philadelphia-positive acute lymphoblastic leukemia patient showing resistance to tyrosine kinase inhibitors.
    Sun H; Yan Z; Zhang S
    Int J Hematol; 2023 Jan; 117(1):134-136. PubMed ID: 36087225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study.
    Kim R; Chalandon Y; Rousselot P; Cayuela JM; Huguet F; Balsat M; Passet M; Chevallier P; Hicheri Y; Raffoux E; Leguay T; Chantepie S; Maury S; Hayette S; Solly F; Braun T; De Prijck B; Cacheux V; Salanoubat C; Farnault L; Guibaud I; Lamarque M; Gastaud L; Lemasle E; Brissot E; Tavernier E; Bilger K; Villate A; Soulier J; Graux C; Lhéritier V; Dombret H; Boissel N; Clappier E
    J Clin Oncol; 2024 Sep; 42(26):3140-3150. PubMed ID: 39028928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of dual color-dual fusion translocation fluorescence in situ hybridization in the detection of bcr/abl fusion gene.
    Wu B; Zhou S; Song L; Liu X
    Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):364-6. PubMed ID: 12408765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
    van Rhee F; Hochhaus A; Lin F; Melo JV; Goldman JM; Cross NC
    Blood; 1996 Jun; 87(12):5213-7. PubMed ID: 8652835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rare e14a3 (b3a3) BCR-ABL fusion in chronic myeloid leukemia in India: the threats and challenges in monitoring minimal residual disease (MRD).
    Vaniawala S; Acharya A; Parekh H; Mukhopadhyaya PN
    Anal Cell Pathol (Amst); 2013; 36(3-4):85-92. PubMed ID: 24072036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
    Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
    Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
    Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
    Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells.
    Tsubaki M; Takeda T; Matsuda T; Kimura A; Tanaka R; Nagayoshi S; Hoshida T; Tanabe K; Nishida S
    BMB Rep; 2023 Feb; 56(2):78-83. PubMed ID: 36195570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
    Yeh CH; Abdool A; Bruey JM
    Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.
    Alikian M; Whale AS; Akiki S; Piechocki K; Torrado C; Myint T; Cowen S; Griffiths M; Reid AG; Apperley J; White H; Huggett JF; Foroni L
    Clin Chem; 2017 Feb; 63(2):525-531. PubMed ID: 27979961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
    Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
    Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.